-
Refugees resettling to the United States and other developed countries frequently suffer from infectious diseases, and can pose diagnostic or therapeutic dilemmas for health care providers in their new homes.
-
This multicenter, randomized, placebo-controlled trial of a synthetic GHRH analogue, tesamorelin (1-44 amino acids from the amino terminal of GHRH with a trans-3-hexenoyl group added to the amino terminal to increase the half-life over native GHRH), randomized 412 patients (86% male) to daily subcutaneous tesamorelin vs placebo for 26 weeks.
-
Sixty-one hospitals in 28 countries participated in a prospective cohort study of hospitalized patients with definite endocarditis.
-
The diagnosis of malaria has traditionally relied upon microscopy. However, microscopic diagnosis is labor intensive and somewhat subjective, and assurance of quality standards can be difficult at best.
-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Though they are the most common infectious complication in hospitals, urinary tract infections (UTIs) get no respect.
-
Recall of a dozen lots of two Haemophilus influenzae type b (Hib) vaccines and suspension of production by a major manufacturer will result in a national shortage that could put children at risk and will certainly trouble physicians and parents in the short run, Julie Gerberding, MD, MPH, director of the Centers for Disease Control and Prevention, warns.
-
Merck & Co. has initiated a voluntary recall in the United States for 10 lots of PedvaxHIB® [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] and two lots of COMVAX® [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine].
-
The Michigan Health & Hospital Association's Keystone Center for Patient Safety & Quality has created a "bladder bundle" of measures to prevent urinary tract infections. Some of the key recommendations for implementation of the bundle are summarized as follows:
-
